Drug-Eluting Stent Players Face Setback With Lower-Paying DRG Assignment
This article was originally published in The Gray Sheet
Executive Summary
A provision that could be included in Medicare "giveback" legislation slated to be taken up by Congress this summer would allow drug-eluting stents to be assigned to a higher-paying diagnosis related group (DRG) midway through the fiscal year
You may also be interested in...
Inpatient Payment Rule Provides No New Tech Add-On Payments For Devices
Medtronic Sofamor Danek's InFuse bone graft/LT-Cage lumbar tapered fusion system does not qualify for a new technology add-on payment under the inpatient prospective payment system (IPPS) fiscal 2003 final rule because the device is FDA-approved only for single-level spinal fusion
Inpatient Payment Rule Provides No New Tech Add-On Payments For Devices
Medtronic Sofamor Danek's InFuse bone graft/LT-Cage lumbar tapered fusion system does not qualify for a new technology add-on payment under the inpatient prospective payment system (IPPS) fiscal 2003 final rule because the device is FDA-approved only for single-level spinal fusion
Thoratec Makes Case For Permanent VAD Higher Medicare Reimbursement
Thoratec is expecting CMS to boost Medicare reimbursement for mechanical cardiac assist device implantation based on data showing that the firm's HeartMate XVE left ventricular assist device (LVAD) is a cost-effective destination therapy for end-stage heart failure patients